Navigation Links
Repligen Announces Conference Call of Fourth Quarter and Fiscal Year 2009 Results
Date:6/4/2009

Thursday, June 11th, 10:00 a.m. EDT

WALTHAM, Mass., June 4 /PRNewswire-FirstCall/ -- Repligen Corporation (Nasdaq: RGEN) announced today that the Company President and Chief Executive Officer, Walter C. Herlihy, Ph.D., will host a conference call and webcast on Thursday, June 11th, 2009 at 10:00 a.m. EDT, to report fourth quarter and fiscal year 2009 financial results and to provide a quarterly update of the Company.

This call is being webcast by Thomson/CCBN and can be accessed via Repligen's website at www.repligen.com. If you are unable to access the webcast via the internet, you may also listen to the live broadcast by calling (800) 295-4740 for domestic calls and (617) 614-3925 for international calls. Participants must provide the following passcode: 30164372. For those who cannot participate in the live conference call, an archive of the audio webcast will be available shortly after the call and may be accessed at www.repligen.com.

About Repligen Corporation

Repligen Corporation is a biopharmaceutical company focused on the development of novel therapeutics for neurological disorders. In addition, we are the world's leading supplier of recombinant Protein A, the sales of which partially fund the advancement of our development pipeline while supporting our financial stability. Repligen's corporate headquarters are located at 41 Seyon Street, Building #1, Suite 100, Waltham, MA 02453. Additional information may be requested from www.repligen.com.

This press release contains forward-looking statements which are made pursuant to the safe harbor provisions of Section 27A
'/>"/>

SOURCE Repligen Corporation
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. Repligen Announces Conference Call of Third Quarter Fiscal Year 2008 Results
2. Repligen Announces Settlement with Bristol-Myers Squibb in Orencia(R) Lawsuit
3. Repligen Reports Fourth Quarter and Fiscal Year 2008 Financial Results
4. Repligen Announces Conference Call of First Quarter Fiscal Year 2009 Results
5. Repligen Receives Research Grants to Support Friedreichs Ataxia Development Program
6. Repligen Announces Publication of Positive Results with Proprietary HDAC Inhibitor in Huntingtons Disease Model
7. Repligen to Present at the 2008 UBS Global Life Sciences Conference Wednesday, September 24th, 1:00 p.m. EDT
8. Repligen to Present at the Rodman & Renshaw 10th Annual Healthcare Conference Monday, November 10th, 4:55 p.m. EST
9. Repligen Announces Conference Call of Third Quarter Fiscal Year 2009 Results
10. Repligen to Present at the BIO CEO & Investor Conference Monday, February 9th, 11:30 a.m. EST
11. Repligen Reports Third Quarter Fiscal Year 2009 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2009)... Reportlinker.com announces that a new ... catalogue: ,, Infectious Disease Molecular ... http://www.reportlinker.com/p0170008/Infectious-Disease-Molecular-Diagnostic-Testing.html ,, The report ... and market needs for major infectious diseases, ... developing and marketing molecular diagnostic technologies and ...
(Date:12/17/2009)... -- Using a novel stem cell based,technology of ... a glioma -- brain cancer -- of a ... Beijing. The treatment shows that the activated,immune system ... as cancer daughter,cells. The amazing outcome of this ... that the future vaccination therapies may be,targeted towards ...
(Date:12/17/2009)... the GLOBALS, ,and PM360 Pharma Choice Awards Programs. , ... ... full-service healthcare communications agency Goble & Associates, Inc. (G&A) recently ... creative and interactive work. , , ,THE RX CLUB AWARDS ... Excellence for the following creative work: Hospira LifeShield ad campaign, ...
(Date:12/16/2009)... Scientists have developed a simple, cheap, accurate test to ... Edinburgh have created a custom-made bacteria that glows green ... buried explosives. , The bacteria can be mixed into ... ground, forms green patches to indicate the presence of ... is cheap to produce, could be delivered from the ...
Breaking Biology Technology:Reportlinker Adds Infectious Disease Molecular Diagnostic Testing 2For the First Time, a Glioma ¨C Brain Cancer ¨C may be Eliminated by a Chinese Research/Medical Team, Using a Novel Stem Cell Based Therapy of Cellonis Biotech, Beijing 2For the First Time, a Glioma ¨C Brain Cancer ¨C may be Eliminated by a Chinese Research/Medical Team, Using a Novel Stem Cell Based Therapy of Cellonis Biotech, Beijing 3For the First Time, a Glioma ¨C Brain Cancer ¨C may be Eliminated by a Chinese Research/Medical Team, Using a Novel Stem Cell Based Therapy of Cellonis Biotech, Beijing 4Goble & Associates Creative Work Awarded at Advertising Industry Competitions 2Goble & Associates Creative Work Awarded at Advertising Industry Competitions 3Goble & Associates Creative Work Awarded at Advertising Industry Competitions 4
... Scheduled for Monday, October 6, 2008 at ... 2 ARCA biopharma, Inc., a,biopharmaceutical company ... cardiovascular diseases, today announced that,Richard Brewer, the ... Michael Bristow, M.D., ARCA,s chairman and chief ...
... Approval would make Zevalin only Radioimmunotherapy in U.S. to be ... ... Cell Therapeutics, Inc. (CTI),(Nasdaq and MTA: CTIC) announced today ... the U.S. Food and Drug,Administration (FDA) for use of Zevalin(R) ...
... - Announcement No. 40/2008, - To OMX Nordic ... announces a grant of license to Roche Diagnostics for,use ... proprietary,LNA(TM) detection technology., Roche Diagnostics will develop its ... Universal ProbeLibrary that is based on Exiqon,s,proprietary LNA(TM) detection ...
Other Biology Technology:ARCA biopharma to Present at JMP Securities Healthcare Focus Conference 2ARCA biopharma to Present at JMP Securities Healthcare Focus Conference 3ARCA biopharma to Present at JMP Securities Healthcare Focus Conference 4ARCA biopharma to Present at JMP Securities Healthcare Focus Conference 5Cell Therapeutics Submits Supplemental Biologics License Application for Zevalin Use in First-Line Consolidation Therapy 2Cell Therapeutics Submits Supplemental Biologics License Application for Zevalin Use in First-Line Consolidation Therapy 3Cell Therapeutics Submits Supplemental Biologics License Application for Zevalin Use in First-Line Consolidation Therapy 4Cell Therapeutics Submits Supplemental Biologics License Application for Zevalin Use in First-Line Consolidation Therapy 5Exiqon A/S Today Announces a Grant of License to Roche Diagnostics 2Exiqon A/S Today Announces a Grant of License to Roche Diagnostics 3
(Date:12/16/2009)... Knowledge and Innovation Community (Climate-KIC)" is a major initiative ... program brings together the expertise of world class partners ... Europe,s innovation capacity to meet the climate change challenge ... a new low-carbon society. In responding to this challenge, ... produce, distribute, and consume goods, and to how we ...
(Date:12/16/2009)... US Secretary of Energy Steven Chu announced today the ... outstanding contributions in research and development supporting the Department ... named today will receive a gold medal, a citation ... a ceremony in Washington, DC early next year., "The ... economic and energy security of the United States are ...
(Date:12/16/2009)... of financial and technical assistance to developing countries around ... to be connected to space technology, but large development ... linked. , Global climate change is also an increasingly ... the poorest countries and communities, which will suffer the ... to a growing demand for information about the state ...
Breaking Biology News(10 mins):Innovation boost to tackle climate change 2Innovation boost to tackle climate change 3Secretary Chu announces 2009 Ernest Orlando Lawrence Award winners 2ESA and World Bank move toward closer collaboration 2ESA and World Bank move toward closer collaboration 3ESA and World Bank move toward closer collaboration 4Forsyth scientists suggest linkages between obesity and oral bacterial infection 9176 1Forsyth scientists suggest linkages between obesity and oral bacterial infection 9176 2The Hispanic got milk 3F Campaign Visits Chicago from July 2 July 10 51122 1The Hispanic got milk 3F Campaign Visits Chicago from July 2 July 10 51122 2Advanced Heart Procedure Treats Growing Problem 51120 1Advanced Heart Procedure Treats Growing Problem 51120 2Advanced Heart Procedure Treats Growing Problem 51120 3
... whale and its large prey, the jumbo squid, are ... depths of 3,000 feet or more. Now, in a ... successful tagging of sperm whales and jumbo squid swimming ... tracking devices have been applied simultaneously to deep-diving predators ...
... cells from the lungs of transplant patients demonstrates for the ... and are not derived from bone marrow, which leads to ... with the rejection of donated organs and with various kinds ... Michigan Health System researchers is significant because of the large ...
... January issue of the journal Cell Metabolism, published by Cell ... formation of a poorly understood type of muscle. Moreover, they ... fibers were able to run farther and at higher work ... lead to novel drugs designed to change the composition of ...
Other Biology News:Tracking sperm whales and jumbo squid 2Tracking sperm whales and jumbo squid 3Tracking sperm whales and jumbo squid 4Tracking sperm whales and jumbo squid 5Tracking sperm whales and jumbo squid 6Type of stem cell found to reside in transplanted lungs 2Type of stem cell found to reside in transplanted lungs 3'Marathon mice' elucidate little-known muscle type 2'Marathon mice' elucidate little-known muscle type 3
... Ciphergen's ProteinChip arrays have been developed ... biological samples. A variety of ProteinChip ... proteins according to their unique biochemical ... spots, allowing side-by-side sample comparison, and ...
Thermal printer paper is used with the thermal printer for the VersaFluor fluorometry systems. Supplied as 10 rolls....
The thermal printer, 120 V, is used to record fluorescence data acquired with the VersaFluor fluorometry systems. The printer includes a cable and power adaptor....
... SR-101 Labeled Substrates (red fluorescence; Ex=590 ... serine protease activation • No lysing, ... Kits utilize cell-permeable, fluorescently labeled inhibitors ... chymotrypsin-like activity in whole living cells. ...
Biology Products: